TY - JOUR
T1 - Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension
T2 - A randomised clinical trial
AU - Nouri-Vaskeh, Masoud
AU - Kalami, Niusha
AU - Zand, Ramin
AU - Soroureddin, Zahra
AU - Varshochi, Mojtaba
AU - Ansarin, Khalil
AU - Rezaee, Haleh
AU - Taghizadieh, Ali
AU - Sadeghi, Armin
AU - Ahangari Maleki, Masoud
AU - Esmailnajad, Azam
AU - Saleh, Parviz
AU - Haghdoost, Mehdi
AU - Maleki, Mehdi
AU - Sharifi, Akbar
N1 - Funding Information:
We would like special thank to Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences. This work was supported by COVID-19 grant from the Tabriz University of Medical Sciences (Grant number: 65204).
Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PY - 2021/6
Y1 - 2021/6
N2 - Background: Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19. Methods: In this randomised clinical trial, hospitalised patients with COVID-19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30-day mortality rate and length of hospital stay. Results: The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value =.068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value =.085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value =.994). The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value =.241). Conclusions: There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.
AB - Background: Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19. Methods: In this randomised clinical trial, hospitalised patients with COVID-19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30-day mortality rate and length of hospital stay. Results: The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value =.068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value =.085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value =.994). The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value =.241). Conclusions: There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85102436997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102436997&partnerID=8YFLogxK
U2 - 10.1111/ijcp.14124
DO - 10.1111/ijcp.14124
M3 - Article
C2 - 33650197
AN - SCOPUS:85102436997
SN - 1368-5031
VL - 75
JO - International Journal of Clinical Practice
JF - International Journal of Clinical Practice
IS - 6
M1 - e14124
ER -